Back to Search Start Over

Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia

Authors :
Schwandt, P.
Elsäßer, R.
Gertz, B.
Augustin, J.
Schmidt, C.
Heil, M.
Seibel, K.
Source :
European Journal of Clinical Pharmacology; September 1994, Vol. 47 Issue: 2 p133-138, 6p
Publication Year :
1994

Abstract

The efficacy and safety of lifibrol, a novel cholesterol-lowering drug, was investigated in a double-blind clinical study in 168 patients with primary hypercholesterolaemia. Placebo and four lifibrol dose groups (150, 300, 450 and 600 mg/day) were tested over a period of 4 weeks.

Details

Language :
English
ISSN :
00316970 and 14321041
Volume :
47
Issue :
2
Database :
Supplemental Index
Journal :
European Journal of Clinical Pharmacology
Publication Type :
Periodical
Accession number :
ejs16150111
Full Text :
https://doi.org/10.1007/BF00194962